(Q35561735)

8 August 2017

1 reference

title

Update on therapy for heart failure (English)

1 reference

8 August 2017

Robert DiBianco

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

8 August 2017

15 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14563505

full work available at URL

22 March 2024

https://api.elsevier.com/content/article/PII:S0002934303002651?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00265-1

https://api.elsevier.com/content/article/PII:S0002934303002651?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00265-1

American Journal of Medicine

22 March 2024

published in

1 reference

8 August 2017

volume

115

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

480-488

1 reference

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Benefits of beta-blocker therapy for heart failure: weighing the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effect of carvedilol on survival in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Impact of multiple risk factor profiles on determining cardiovascular disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971-1992.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

The progression from hypertension to congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Chronic heart failure in the United States: a manifestation of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Association of serum digoxin concentration and outcomes in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Angiotensin II type 1 receptor blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Functional effects of endogenous bradykinin in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Bradykinin–evoked sensitization of airway sensory nerves: A mechanism for ACE–inhibitor cough

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Plasma bradykinin in angio-oedema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Aldosterone and spironolactone in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Chronic administration of aldosterone depresses baroreceptor reflex function in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

Major beta blocker mortality trials in chronic heart failure: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900265-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

series ordinal

30

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00265-1

Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure

22 March 2024

series ordinal

34

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00265-1

Warfarin versus aspirin in paroxysmal atrial fibrillation

22 March 2024

series ordinal

35

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00265-1

22 March 2024

Identifiers

1 reference

8 August 2017

1 reference